2-甲基异邻苯二甲酸二甲酯 | 28269-31-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-甲基异邻苯二甲酸二甲酯
• 英文名称: dimethyl 2-methylisophthalate
• 英文别名: 2-Methyl-isophthalsaeure-dimethylester；dimethyl 2-methylbenzene-1,3-dicarboxylate
• CAS: 28269-31-0
• 化学式: C₁₁H₁₂O₄
• 分子量: 208.214
• InChiKey: UPGQXOHLGDXBJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  274.7±20.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2917399090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319

反应信息

• 作为反应物：
  描述：

  2-甲基异邻苯二甲酸二甲酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 为溶剂， 反应 0.5h， 以93%的产率得到dimethyl 2-(bromomethyl)-1,3-benzenedicarboxylate
  参考文献：
  名称：

  Synthesis of 9-Methoxymethyl-18-methyl-2,11-dithia[3.3]metacyclophane: a Dithia[3.3]metacyclophane With a Protected Internal Benzylic Functional Group

  摘要：

  本文介绍了一种在 C9 位带有苄基官能团（甲氧基甲基）的二硫[3.3]偏环烷的合成路线。不过，苄基官能团必须在合成方案的后期引入，以优化总产率。只分离出了所需的二硫代环烷（7）的反异构体。如 1H n.m.r. 光谱所示，整个甲氧基甲基位于对侧苯环的屏蔽区内。然而，通过重排-消除顺序将反（7）转化为新型芳香系统（5b）的尝试失败了。

  DOI：

  10.1071/ch9901783
• 作为产物：
  描述：

  间苯二甲腈 在 氢氧化钾 、 硫酸 、 lithium diisopropyl amide 作用下， 生成 2-甲基异邻苯二甲酸二甲酯
  参考文献：
  名称：

  Design and Synthesis of a Trifunctional Chiral Porphyrin with C2 Symmetry as a Chiral Recognition Host for Amino Acid Esters

  摘要：

  An intrinsic chiral recognition host, (R,R)- or (S,S)-[trans-5,15-bis(2-hydroxyphenyl)-10-{2,6-bis((methoxycarbonyl)methyl)phenyl}-2,3,17,18-tetraethylporphyrinato]zinc(II) (1), was synthesized by the coupling between (3,3',4,4'-tetraethyl-5,5'-bis(alpha-hydroxy-2-methoxybenzyl)-2,2'-dipyrryl)methane (8) and dimethyl 2-(bis(2-pyrryl)-methyl)-1, 3-benzenediacetate (16). This pyrrylmethanol method made it possible to perform the regiospecific coupling between differently functionalized dipyrromethane units. Host 1 was designed to have three recognition elements: metal coordination, hydrogen bond donor, and hydrogen bond acceptor (and/or steric repulsion) groups. These groups are arranged in a convergent fashion, forming a chiral recognition pocket. Host 1 was resolved into two enantiomers, (+)-1 and (-)-1. The binding constants in CHCl3 were determined by UV-vis titration. Host (+)-1 was found to show an enantioselectivity of 2.0-2.8 in respect to L- and D-enantiomers of Ile-OMe, Leu-OMe, Leu-OBzl, Val-OMe, Pro-OMe, and Phe-OMe. Host (+)-1 showed an enantioselectivity of 0.47 in respect to L- and D-enantiomers of serine benzyl ester, indicating that the enantioselectivity was reversed. Reference porphyrins 2-4, which lack some of recognition groups, were also synthesized by the pyrrylmethanol method to clarify the roles of the recognition groups of (+)-1 in thermodynamics of the binding processes. Total free energy change upon binding of L- and D-Ile-OMe to host (+)-1 (Delta G degrees(total) for L, -5.05, and D, -4.46 kcal/mol) was separated into three terms: metal coordination energy (Delta G degrees(Zn)), -4.15 kcal/mol; hydrogen bond energy (Delta Delta G degrees(OH)), -1.30 kcal/mol; and steric repulsion energy (Delta Delta G degrees(COOMe)(L) or Delta Delta G degrees(COOMe)(D)), +0.40 kcal/mol for L- and +0.99 kcal/mol for D-Ile-OMe. The third recognition group (CH(2)CO(2)Me) of (+)-1 was found to destabilize the complexes due to steric repulsions. In contrast, the CH(2)CO(2)Me group was found to stabilize the complex between D-Ser-OBzl and (+)-1, suggesting that hydrogen bonding between the OH group of serine and the C=O group of (+)-1 takes place. On the basis of these thermodynamic studies, chiral recognition was found to be achieved by cooperative functions of these three recognition groups.

  DOI：

  10.1021/ja00089a013

文献信息

• [EN] (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING<br/>[FR] DÉRIVÉS DE (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE ET COMPOSÉS ASSOCIÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA BÊTA-SÉCRÉTASE POUR LE TRAITEMENT
  申请人：COMENTIS INC

  公开号：WO2009042694A1

  公开（公告）日：2009-04-02

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

  本发明提供了新颖的β-分泌酶抑制剂及其使用方法，包括用于治疗阿尔茨海默病的方法。
• Novel Photoluminescent Polymers Containing Oligothiophene and <i>m</i>-Phenylene-1,3,4-oxadiazole Moieties:  Synthesis and Spectroscopic and Electrochemical Studies
  作者：Hong Meng、Wei Huang

  DOI：10.1021/jo991359c

  日期：2000.6.1

  Three conjugated polymers containing oligothiophene units (from one to three thiophene rings) and aromatic 1,3,4-oxadiazole moieties have been successfully synthesized. The polymer structures were characterized and confirmed by (1)H and (13)C NMR, FT-IR, and elemental analysis. Thermogravimetric analysis demonstrated that the polymers are highly thermal stable. Tunable absorption (from 342 to 428 nm)

  已经成功合成了三种包含低聚噻吩单元（从一个到三个噻吩环）和芳香族1,3,4-恶二唑部分的共轭聚合物。通过（1）H和（13）C NMR，FT-IR和元素分析来表征和确认聚合物结构。热重分析表明该聚合物是高度热稳定的。观察到了聚合物的可调吸收（342-428 nm）和荧光（411-558 nm）特性。电化学研究表明，可以调节新聚合物的LUMO和HOMO能级。电化学分析还表明，该聚合物对于p型和n型电荷载流子均具有良好的电荷注入性能，以及良好的颜色可调发光和成膜性能，
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS<br/>[FR] MODULATEURS DU RÉCEPTEUR X4 DE LA PROTÉINE G ASSOCIÉE À MAS ET PRODUITS ET PROCÉDÉS ASSOCIÉS
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2020198537A1

  公开（公告）日：2020-10-01

  Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

  提供了一种通过接触MRGPR X4或向需要的受试者施用具有以下结构的化合物的有效量，从而对MRGPR X4进行调节，或更具体地用于治疗依赖于MRGPR X4的疾病，其中该结构为Formula (I): (I)或其药学上可接受的异构体、拉克酸盐、水合物、溶剂合物、同位素或盐，其中n、x、A、Q1、Q2、Z、R、R1、R2、R3、R4和R5的定义如本文所述。还提供了含有这些化合物的药物组合物，以及化合物本身。
• Cis-Dimethyldihydropyrene synthesis
  作者：Reginald H. Mitchell、Mahima Chaudhary、Toshihiro Kamada、Paul D. Slowey、Richard Vaughan Williams

  DOI：10.1016/s0040-4020(01)87591-8

  日期：1986.1

  A new route to dihydropyrene precursors, 1,3-bis(bromomethyl)-2-substituted-benzenes, has been found, which starts from the readily available hexachlorocyclopentadiene and 3-substituted acrylic esters. Utilization of an intermediate in this sequence, 1,3-bis(bromomethyl)-4,5-dichlorotoluenc, has opened up a route to the relatively inaccessible cis-dimethyldihydropyrenes to allow study of their chemistry

  已经发现了一种新的二氢py前体1,3-双（溴甲基）-2-取代的苯的途径，它是从容易获得的六氯环戊二烯和3-取代的丙烯酸酯开始的。利用该顺序的中间体1，3-双（溴甲基）-4，5-二氯甲苯，开辟了一条通往相对难以接近的顺式-二甲基二氢吡啶的途径，以研究其化学性质。
• ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY
  申请人：Ghosh Arun K.

  公开号：US20100286145A1

  公开（公告）日：2010-11-11

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

  本发明提供了新型的β-分泌酶抑制剂及其使用方法，包括治疗阿尔茨海默病的方法。